Lexeo Therapeutics, Inc.

The momentum for this stock is not very good. Lexeo Therapeutics, Inc. is not a good value stock. Lexeo Therapeutics, Inc. is not a good growth stock. Lexeo Therapeutics, Inc. is not very popular among insiders. Lexeo Therapeutics, Inc. is a mediocre stock to choose.
Log in to see more information.
LXEO Fundamental Data by TradingView

News

Lexeo Therapeutics to Participate in Upcoming Investor Conferences
Lexeo Therapeutics to Participate in Upcoming Investor Conferences

Globe Newswire NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined...\n more…

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives $22.14 Consensus PT from Analysts
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives $22.14 Consensus PT from Analysts

Zolmax Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) has earned an average recommendation of "Buy" from the nine ratings firms that are currently covering the firm, Marketbeat.com reports. Eight...\n more…

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives $22.14 Consensus PT from Brokerages
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives $22.14 Consensus PT from Brokerages

Zolmax Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) has received an average rating of "Buy" from the nine brokerages that are currently covering the stock, MarketBeat Ratings reports. Eight...\n more…

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives $22.14 Average Price Target from Analysts
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives $22.14 Average Price Target from Analysts

Ticker Report Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) has earned a consensus recommendation of "Buy" from the nine ratings firms that are currently covering the firm, Marketbeat.com reports. Eight...\n more…

FY2024 EPS Estimates for Lexeo Therapeutics, Inc. Decreased by Chardan Capital (NASDAQ:LXEO)
FY2024 EPS Estimates for Lexeo Therapeutics, Inc. Decreased by Chardan Capital (NASDAQ:LXEO)

Ticker Report Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) - Equities research analysts at Chardan Capital decreased their FY2024 earnings estimates for shares of Lexeo Therapeutics in a research note...\n more…

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) to Post FY2025 Earnings of ($2.46) Per Share, Chardan Capital Forecasts
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) to Post FY2025 Earnings of ($2.46) Per Share, Chardan Capital Forecasts

Ticker Report Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) - Investment analysts at Chardan Capital issued their FY2025 EPS estimates for shares of Lexeo Therapeutics in a research report issued on...\n more…